CARIBOU BIOSCIENCES
Caribou Biosciences is a operator of a medical technology company intended to analyze cell and genome engineering. The company specializes in cellular engineering and analysis based on the CRISPR-Cas9 technology platform which paired with a guide RNA, cuts double-stranded DNA and allows for specific changes to DNA, enabling development of therapeutics for agricultural biotechnology, industrial biotechnology and basic and applied biological research.
CARIBOU BIOSCIENCES
Industry:
Biotechnology Health Care Therapeutics
Founded:
2011-01-01
Address:
Berkeley, California, United States
Country:
United States
Website Url:
http://www.cariboubio.com
Total Employee:
101+
Status:
Active
Contact:
510-982-6030
Email Addresses:
[email protected]
Total Funding:
167.7 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager Font Awesome Domain Not Resolving Apache
Similar Organizations
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Ikena Oncology
Ikena Oncology is a biotechnology company that advances new immunometabolic therapies for cancer.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
LifeSci Venture Partners
LifeSci Venture Partners investment in Series C - Caribou Biosciences
Avego Bioscience Capital
Avego Bioscience Capital investment in Series C - Caribou Biosciences
Maverick Ventures
Maverick Ventures investment in Series C - Caribou Biosciences
Ridgeback Capital
Ridgeback Capital investment in Series C - Caribou Biosciences
Farallon Capital Management
Farallon Capital Management investment in Series C - Caribou Biosciences
Avidity Partners
Avidity Partners investment in Series C - Caribou Biosciences
Janus Henderson Investors
Janus Henderson Investors investment in Series C - Caribou Biosciences
Adage Capital Management
Adage Capital Management investment in Series C - Caribou Biosciences
AbbVie Biotech Ventures
AbbVie Biotech Ventures investment in Series C - Caribou Biosciences
Heritage Group
Heritage Group investment in Series C - Caribou Biosciences
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2014-11-18 | Intellia Therapeutics | Caribou Biosciences investment in Series A - Intellia Therapeutics | 15 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2020-05-15 | Cherry Thomas joins Caribou as SVP of clinical development; Artax locks in Joseph Lobacki as CEO |
Official Site Inspections
http://www.cariboubio.com Semrush global rank: 3.31 M Semrush visits lastest month: 4.88 K
- Host name: ec2-54-176-110-96.us-west-1.compute.amazonaws.com
- IP address: 54.176.110.96
- Location: San Jose United States
- Latitude: 37.3388
- Longitude: -121.8914
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 95141
More informations about "Caribou Biosciences"
Caribou Biosciences - Crunchbase Company Profile
Caribou Biosciences is an operator of a medical technology company intended to analyze cell and genome engineering. The company specializes in cellular engineering and analysis based on the CRISPR-Cas9 technology platform …See details»
Caribou Biosciences | Developing Sophisticated …
Armored for enhanced activity. We believe armoring is the key to unlocking the full potential of allogeneic cell therapies. We use our chRDNA technologies to armor our cell therapies through multiple genome-editing strategies, including …See details»
Caribou Biosciences - LinkedIn
Caribou Biosciences is a leading clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases.See details»
Investors | Caribou Biosciences, Inc.
Nov 6, 2024 Caribou Biosciences, Inc. 2929 7th Street, Suite 105 Berkeley, CA 94710 Tel: 510-982-6030See details»
Release details - Caribou Biosciences, Inc.
Nov 8, 2021 Dr. Richardson-Heron most recently served as Pfizer’s chief patient officer where she was responsible for developing the organization’s global strategy to advance patient …See details»
Caribou Biosciences CEO and Key Executive Team | Craft.co
Caribou Biosciences's President and Chief Executive Officer is Rachel Haurwitz. Other executives include Barbara McClung, Chief Legal Officer and Corporate Secretary; Jason O'Byrne, Chief …See details»
Caribou Biosciences Appoints Biotechnology Industry Veteran
Sep 29, 2021 In that role, Ms. Zheng led the technical operations organization and helped advance the company’s product pipeline, including contributing to the approval of Libmeldy® …See details»
Company: Caribou Biosciences - crisprmedicinenews.com
Caribou Biosciences develops novel allogeneic CAR-T and CAR-NK cell therapies. It uses CRISPR-Cas9 and CRISPR-Cas12a to knock out multiple genes, such as TRAC (endogenous …See details»
Caribou Biosciences - Overview, News & Similar companies
Aug 28, 2024 Caribou Biosciences contact info: Phone number: (510) 982-6030 Website: www.cariboubio.com What does Caribou Biosciences do? Caribou Biosciences, Inc., a clinical …See details»
Leadership | Board of Directors | SAB | Caribou Biosciences
She serves on the board of directors of Seer, Inc. and the Biotechnology Innovation Organization (BIO). Rachel earned an AB in biological sciences from Harvard College and a PhD in …See details»
Caribou Biosciences Appoints Biotechnology Industry Veteran Ran …
BERKELEY, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical …See details»
Caribou Biosciences to Participate in Upcoming Investor Conferences
BERKELEY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today …See details»
Caribou Biosciences Provides Regulatory Update on CB-010 …
Dec 12, 2023 Follow us @CaribouBio and visit www.cariboubio.com. Forward-looking statements This press release contains forward-looking statements within the meaning of the …See details»
Caribou Biosciences Raises $115M Series C Financing to Advance …
Mar 3, 2021 BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today the …See details»
Caribou Biosciences Presents Encouraging Clinical Data from CB …
Jun 3, 2024 Caribou is advancing a pipeline of clinical-stage off-the-shelf cell therapies from its CAR-T cell platform as readily available treatments for patients with hematologic malignancies …See details»
Job opportunities at Caribou Biosciences
Caribou Biosciences, Inc. and other biotech companies have recently been made aware of a growing number of email scams targeting job candidates in our industry. Our recruiters at …See details»
Allogeneic T cells and NK cells | chRDNAs | Caribou Biosciences
Encore: A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) for relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 …See details»
CAR-T cell therapy platform | Caribou Biosciences
CB-011 armored with immune cloaking to prevent both T and NK cell-mediated immune rejection. CB-011, an allogeneic anti-BCMA CAR-T cell therapy, has four edits engineered to target …See details»
Pipeline | CB-010 | CB-011 | CB-012 | CB-020 | Caribou Biosciences
Armoring: checkpoint disruption Target: CD19 Editing: PD-1 KO Indication: r/r B-NHL FDA Designations: Regenerative Medicine Advanced Therapy (RMAT) Fast Track Orphan Drug. …See details»